WallStSmart

Regeneron Pharmaceuticals Inc (REGN)vsTurn Therapeutics Inc. Common Stock (TTRX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

REGN leads profitability with a 31.4% profit margin vs 0.0%. REGN earns a higher WallStSmart Score of 58/100 (C).

REGN

Buy

58

out of 100

Grade: C

Growth: 4.0Profit: 7.5Value: 7.3Quality: 7.3
Piotroski: 3/9Altman Z: 4.68

TTRX

Avoid

16

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 6.5
Piotroski: 2/9Altman Z: -15.78
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

REGNSignificantly Overvalued (-165.8%)

Margin of Safety

-165.8%

Fair Value

$281.93

Current Price

$749.47

$467.54 premium

UndervaluedFair: $281.93Overvalued

Intrinsic value data unavailable for TTRX.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

REGN6 strengths · Avg: 8.8/10
Profit MarginProfitability
31.4%10/10

Keeps 31 of every $100 in revenue as profit

Altman Z-ScoreHealth
4.6810/10

Safe zone — low bankruptcy risk

Market CapQuality
$78.41B9/10

Large-cap with strong market position

P/E RatioValuation
17.9x8/10

Attractively priced relative to earnings

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
23.1%8/10

Strong operational efficiency at 23.1%

TTRX1 strengths · Avg: 10.0/10
Debt/EquityHealth
0.0610/10

Conservative balance sheet, low leverage

Areas to Watch

REGN4 concerns · Avg: 3.3/10
PEG RatioValuation
1.564/10

Expensive relative to growth rate

Revenue GrowthGrowth
2.5%4/10

2.5% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-2.6%2/10

Earnings declined 2.6%

TTRX4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$98.35M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : REGN

The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.

Bull Case : TTRX

The strongest argument for TTRX centers on Debt/Equity.

Bear Case : REGN

The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.

Bear Case : TTRX

The primary concerns for TTRX are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

REGN is growing revenue faster at 2.5% — sustainability is the question.

Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

REGN scores higher overall (58/100 vs 16/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Regeneron Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.

Turn Therapeutics Inc. Common Stock

HEALTHCARE · BIOTECHNOLOGY · USA

Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village, California.

Want to dig deeper into these stocks?